Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation?
The study aimed to investigate the involvement of nitric oxide (NO) in maneb (MB)- and paraquat (PQ)-induced Parkinson's disease (PD) phenotype in mouse and its subsequent contribution to lipid peroxidation. Animals were treated intraperitoneally with or without MB and PQ, twice a week for 3, 6 and 9 weeks. In some sets of experiments (9 weeks treated groups), the animals were treated intraperitoneally with or without inducible nitric oxide synthase (iNOS) inhibitor-aminoguanidine, tyrosine kinase inhibitor-genistein, nuclear factor-kappa B (NF-kB) inhibitor-pyrrolidine dithiocarbamate (PDTC) or p38 mitogen activated protein kinase (MAPK) inhibitor-SB202190. Nitrite content and lipid peroxidation were measured in all treated groups along with respective controls. RNA was isolated from the striatum of control and treated mice and reverse transcribed into cDNA. RT-PCR was performed to amplify iNOS mRNA and western blot analysis was done to check its protein level. MB- and PQ-treatment induced nitrite content, expressions of iNOS mRNA and protein and lipid peroxidation as compared with respective controls. Aminoguanidine resulted in a significant attenuation of iNOS mRNA expression, nitrite content and lipid peroxidation demonstrating the involvement of nitric oxide in MB- and PQ-induced lipid peroxidation. Genistein, SB202190 and PDTC reduced the expression of iNOS mRNA, nitrite content and lipid peroxidation in MB- and PQ-treated mouse striatum. The results obtained demonstrate that nitric oxide contributes to an increase of MB- and PQ-induced lipid peroxidation in mouse striatum and tyrosine kinase, p38 MAPK and NF-kB regulate iNOS expression.
Gupta
Satya Prakash
SP
Indian Institute of Toxicology Research (Council of Scientific and Industrial Research), Mahatma Gandhi Marg, Lucknow, UP, India.
Patel
Suman
S
Yadav
Sharawan
S
Singh
Anand Kumar
AK
Singh
Seema
S
Singh
Mahendra Pratap
MP
D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D006146:Guanidines / Q000494:pharmacology; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008344:Maneb / Q000633:toxicity*; D051379:Mice; D009569:Nitric Oxide / Q000502:physiology*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D009573:Nitrites / Q000378:metabolism; D010269:Paraquat / Q000633:toxicity*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism*; D010575:Pesticides / Q000633:toxicity*; D010641:Phenotype; D012333:RNA, Messenger / Q000096:biosynthesis; D015290:Second Messenger Systems / Q000502:physiology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D006146:Guanidines; D009573:Nitrites; D010575:Pesticides; D012333:RNA, Messenger; D008344:Maneb; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D014446:Tyrosine 3-Monooxygenase; D010269:Paraquat; C004479:pimagedine
Trends Neurosci. 1989 Oct;12(10):366-75
2479133
Anal Biochem. 1976 May 7;72:248-54
942051
J Immunol. 1998 Nov 1;161(9):4950-9
9794431
Mol Cell Neurosci. 2000 Dec;16(6):724-39
11124893
Brain Res Brain Res Rev. 1999 Aug;30(2):153-63
10525172
J Neuropathol Exp Neurol. 1998 Apr;57(4):338-42
9600227
J Neurochem. 2003 Jan;84(2):336-46
12558996
Brain Res. 2006 Apr 7;1081(1):9-18
16510128
Br J Pharmacol. 1995 Jan;114(2):482-8
7533621
Mol Biotechnol. 2008 Sep;40(1):59-68
18386188
Rejuvenation Res. 2009 Jun;12(3):185-97
19594327
Am J Physiol Renal Physiol. 2002 Sep;283(3):F559-68
12167608
Nat Rev Drug Discov. 2002 Dec;1(12):939-50
12461516
FEBS Lett. 1995 May 15;364(3):279-82
7758583
Neurotoxicol Teratol. 2007 Sep-Oct;29(5):578-85
17532186
Br J Cancer Suppl. 1987 Jun;8:46-52
2820459
Diabetes. 1998 Jul;47(7):1114-20
9648836
J Neurosci Res. 2005 Sep 15;81(6):874-82
16041799
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4900-5
19273858
Am J Physiol. 1995 May;268(5 Pt 1):L699-722
7762673
Lancet. 1990 Apr 21;335(8695):948-52
1691427
Diabetes Metab Res Rev. 1999 Jul-Aug;15(4):283-8
10495477
Life Sci. 2006 Oct 12;79(20):1895-905
16978658
Pharmacol Ther. 2006 Jan;109(1-2):33-41
16005074
Indian J Biochem Biophys. 2006 Apr;43(2):69-81
16955754
Brain Res. 1996 Aug 5;729(1):102-9
8874881
Prog Brain Res. 1998;118:215-29
9932444
Restor Neurol Neurosci. 2000;16(2):135-142
12671216
Cell Mol Biol (Noisy-le-grand). 2007 May 30;53(5):19-28
17543230
Clin Chim Acta. 1998 Nov;278(1):45-53
9877123
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4
2154753
Anal Biochem. 1979 Jun;95(2):351-8
36810
Ann N Y Acad Sci. 2002 May;962:332-46
12076985
Endocrinology. 2006 Feb;147(2):662-71
16293660
Biochem Pharmacol. 1986 Jan 1;35(1):1-6
2416318
Environ Health Perspect. 1984 Apr;55:37-46
6329674
Biochim Biophys Acta. 1999 May 5;1411(2-3):351-69
10320668
Environ Health Perspect. 2005 Sep;113(9):1263-70
16140639
Toxicology. 2005 Mar 15;208(2):273-88
15691591
Neurobiol Dis. 2002 Jul;10(2):119-27
12127150
Toxicology. 2005 Mar 15;208(2):207-12
15691585
Brain Res. 1999 Mar 27;823(1-2):1-10
10095006
J Neurosci. 2000 Dec 15;20(24):9207-14
11124998
Exp Biol Med (Maywood). 2004 Oct;229(9):964-70
15388893
Fundam Clin Pharmacol. 1999;13(5):535-40
10520725
Neurobiol Aging. 2012 Feb;33(2):404-15
20371137
Glia. 1999 Oct;28(1):13-24
10498818
Chem Res Toxicol. 1996 Jul-Aug;9(5):836-44
8828918
Brain Res. 2000 Aug 11;873(2):225-34
10930548
J Neurochem. 2000 May;74(5):2213-6
10800968
Methods Enzymol. 1996;268:142-51
8782580
J Cell Biochem. 2001 Aug 1-9;83(2):271-80
11573244
Nat Med. 1999 Dec;5(12):1403-9
10581083
Neuroscience. 2009 Mar 31;159(3):927-35
19302833
J Neurochem. 1999 Jan;72(1):310-7
9886083